It is our intention to pursue prospective targets that are focused on health care and biopharma. Sarissa will target businesses with valuations of $500 million to $1 billion that have the potential to be substantially greater over time due to their underlying business characteristics and growth opportunities as a public company. Our focus will be on the health-care industry […]

Supernova Partners Acquisition Company, Inc., a newly formed blank check company, was established by Spencer Rascoff, Alexander Klabin, Robert Reid and Michael Clifton to leverage their extensive experience in acquiring, building, operating and scaling businesses in constantly evolving environments. We intend to partner with an advantaged growth company that benefits from thematic shifts and tech-enabled […]

We intend to focus our search on the financial technology sector, which complements the expertise of our management team. We currently intend to concentrate our efforts identifying businesses in the financial services industry with an enterprise value of approximately $600 million to $1.3 billion, with particular emphasis on businesses that are providing or changing technology for […]

We intend to capitalize on our management team’s background to identify and acquire a business in the life sciences industry. In particular, we will target companies in the biotechnology sector where our management team has extensive experience with a focus on identifying target businesses in developed countries including, but not limited to, the United States […]

We intend to concentrate our efforts in identifying businesses in the media and entertainment industries, with a focus on differentiated product and service offerings. In particular, we expect to seek assets that target three broad themes: (1) innovative platforms that support evolving consumer trends; (2) next-generation technology that may unlock new markets and strong growth; and (3) traditional […]

The chromatin regulatory system orchestrates gene expression–the turning on and off of genes–which is fundamental to how all our cells function. Breakdowns in this system lead to a wide range of diseases impacting millions of patients. Understanding the mechanism of how this system works could lead to an entirely new class of therapeutics. To our […]

We intend to focus on businesses primarily operating in the health care and health care provider space in North America and Asia-Pacific. Possible targets may include hospitals or hospital networks, specialty clinics chains, chronic disease health care service providers, telemedicine/digital health providers and/or associated technology/platform enablers, or artificial intelligence/big data enabled diagnostic providers.  We believe the […]

  We intend to focus our search for an initial business combination on companies within the broader consumer technology ecosystem that are either consumer-facing or support the infrastructure of consumer applications (“apps”) with enterprise valuations in an approximate valuation range of $1.0 billion to $3.0 billion. We intend to specifically focus on companies that have created, or […]

We intend to focus our search for a target business in the energy value chain in North America with a particular focus on opportunities aligned with energy transition and sustainability themes.  Our sponsor is an affiliate of a private investment fund managed by Apollo. Leon Black, Joshua Harris and Marc Rowan, Apollo’s managing partners, have […]

  We are a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. We use our proprietary technology, Cell Squeeze, to physically squeeze cells through a microfluidic chip, temporarily opening the cell membrane and enabling biologic material of interest, or cargo, to diffuse into the cell. This […]